• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Equicapita Announces Acquisition of Shaw Group of Dental Laboratories

Share:

December 24, 2018

Equicapita Income Trust and Equicapita Investment Corp. are pleased to announce the completion of the acquisition of Shaw Group of Dental Laboratories  by a wholly-owned subsidiary of Equicapita.

Founded in 1944, Shaw Group is one of the leading networks of dental laboratories in Ontario, with locations in Toronto, London, Ottawa, Kingston and Brampton. Shaw Group, whose diverse customer base includes over 1,500 dentists, has an established reputation for technical leadership and outstanding customer service.

“The opportunity to acquire a successful healthcare product supply business with a growing base of recurring revenue adds both geographic and industry diversification to Equicapita’s investment portfolio. Jim Kerr, Shaw Group’s owner-operator, and the other members of Shaw Group’s management team have consistently demonstrated their commitment to building the business and supporting its extensive customer base” said Equicapita’s Managing Director, Eastern Canada, Adam Jezewski. “Equicapita has targeted investment opportunities in mature healthcare businesses due to the non-cyclical, growing demand for their products and services and favorable long-term outlook, driven by an aging population. In addition to meeting these criteria, Shaw Group has committed executive and laboratory managers and a talented group of technical, sales and administrative staff. We are fortunate and excited to have the opportunity to work with the entire Shaw Group team to continue strengthening and growing the business going forward”.

Equicapita and our new Shaw Group colleagues will continue building the legacy that Jim Kerr has worked tirelessly and passionately to build. “From our initial meetings with Shaw Group management and visits to each laboratory we realized that Shaw Group has a unique and strong culture. We’re grateful to Jim for his decision to entrust Equicapita with continuing his legacy at Shaw Group and we are committed to supporting the ongoing growth and success of the business.” said Michael Cook, co-founder and Director of Equicapita.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Consistent with Equicapita’s investment mandate of assembling a diversified portfolio of long-established Canadian businesses, Shaw Group has 74 years of operating history serving dentists in communities across Ontario and the northern U.S. Shaw Group’s history of generating consistent, profitable growth, along with the continuity of operations by its dedicated staff and excellent customer and supplier relationships, represent cornerstones of Equicapita’s investment strategy.

Shaw Group is Equicapita’s tenth portfolio company acquisition, its first healthcare investment and the first investment completed by Equicapita’s Eastern Canadian office since its opening in April 2018. Equicapita’s deal team was led by Adam Jezewski, with key contributions from Hass Keshavji, Kerri Furlong and Matt Barr. Equicapita retained Norton Rose Fulbright Canada LLP as legal advisors in connection with the Acquisition.

Date: December 24, 2018

Source: Cision

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • American Cancer Society, Roundtrip Partner to Enable Transportation for Cancer PatientsAmerican Cancer Society, Roundtrip Partner to Enable Transportation for Cancer Patients
  • 60% of pharma companies using or trying blockchain – survey60% of pharma companies using or trying blockchain – survey
  • Reema Health Secures $8M for Personalized, Community-Based Health PlatformReema Health Secures $8M for Personalized, Community-Based Health Platform
  • Evidation Health Lands $45M to Expand into Virtual Health Market, Appoints Chief Commercial OfficerEvidation Health Lands $45M to Expand into Virtual Health Market, Appoints Chief Commercial Officer
  • How Will AI Change Healthcare? Robot-Assisted Surgery And Virtual Nurses Are Just The StartHow Will AI Change Healthcare? Robot-Assisted Surgery And Virtual Nurses Are Just The Start
  • CB Scientific, Inc. Announces Definitive Agreement to Acquire Cardiolink Corporation, an Independent Diagnostic Testing Facility (IDTF)CB Scientific, Inc. Announces Definitive Agreement to Acquire Cardiolink Corporation, an Independent Diagnostic Testing Facility (IDTF)
  • Apex Physics Partners Continues Midwest Expansion through Partnership with Advanced Medical PhysicsApex Physics Partners Continues Midwest Expansion through Partnership with Advanced Medical Physics
  • InvaGen (a Cipla subsidiary) Announces Acquisition Agreement with Avenue Therapeutics for Specialty Hospital Business in the U.S.InvaGen (a Cipla subsidiary) Announces Acquisition Agreement with Avenue Therapeutics for Specialty Hospital Business in the U.S.

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications